The Nomination Committee of Sleep Cycle, consisting of Martin Anthonsen (MCGA AB and H265 AB), Erik Olsson (GLA Invest SA), Erik Bertilsson (Lancelot Asset Management AB), and Anne Broeng (Chairperson of the Board), proposes that the Board of Directors of Sleep Cycle be increased by one member and that Christian Kanstrup be elected as new member of the Board of Directors.

“I am pleased with the Nomination Committee’s proposal to elect Christian Kanstrup as new member of the Board of Directors of Sleep Cycle. Christian Kanstrup brings deep expertise from the medtech sector and extensive experience from partnerships in the US market. His strategic background will be highly valuable as Sleep Cycle continues to strengthen its position as a global leader in digital sleep health,” says Anne Broeng, Chairperson of the Board.

Christian Kanstrup, born 1972, holds a Master’s degree in Economics from the University of Copenhagen. Most recently, he served as CEO of Evaxion, listed on Nasdaq (US), and prior to that as Executive Vice President for Nordics, Baltics and UK at Mediq. Christian has extensive experience from senior positions within Novo Nordisk, including Senior Vice President for Biopharm Operations, Senior Vice President for Strategy, Access and Marketing, and General Manager for Region China. Since 2018, Christian is a board member of the listed company NNIT, where he also is a member of the audit and remuneration committees, and since 2024, he is the Chairperson of the Board of Directors of InnoStrat. Christian Kanstrup is considered to be independent in relation to the company and the executive management, as well as the company’s major shareholders. Christian holds no shares in Sleep Cycle.

Further information about the Extraordinary General Meeting will be provided in the notice convening the meeting, which will be published in a separate press release.

For further information, please contact:
Martin Anthonsen, Chairperson of the Nomination Committee
+46 72 197 8000
investor@sleepcycle.com